| Citation: | Ding Peng, Li Hao, Zhuang Quan, et al. Research progress in the effect of immunosuppressive agents on liver fibrosis after renal transplantation[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 603-607. doi: 10.3969/j.issn.1674-7445.2019.05.023
|
| [1] |
CRENESSE D, LAURENS M, HEURTEAUX C, et al. Rat liver ischemia-reperfusion-induced apoptosis and necrosis are decreased by FK506 pretreatment[J]. Eur J Pharmacol, 2003, 473(2-3):177-184. doi: 10.1016/S0014-2999(03)01977-0
|
| [2] |
GUNDERSON A, SAID A. Liver disease in kidney transplant recipients[J]. Transplant Rev (Orlando), 2015, 29(1):1-7. DOI: 10.1016/j.trre.2014.08.002.
|
| [3] |
CONTE C, SECCHI A. Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention[J]. Acta Diabetol, 2018, 55(8):763-779. DOI: 10.1007/S00592-018-1137-8.
|
| [4] |
ANDRADE AR, BITTENCOURT PL, CODES L, et al. New onset diabetes and non-alcoholic fatty liver disease after liver transplantation[J]. Ann Hepatol, 2017, 16(6):932-940. DOI: 10.5604/01.3001.0010.5285.
|
| [5] |
MIKOLASEVIC I, ORLIC L, HRSTIC I, et al. Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation[J]. Hepatol Res, 2016, 46(9):841-852. DOI: 10.1111/hepr.12642.
|
| [6] |
FELIPE C, FERREIRA AN, DE PAULA M, et al. Incidence and risk factors associated with cytomegalovirus infection after thetreatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy[J]. Transpl Infect Dis, 2019:e13106. DOI: 10.1111/tid.13106.
|
| [7] |
KESIRAJU S, SRIKANTI P, SAHARIAH S. Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends[J]. Virusdisease, 2017, 28(3):233-241. DOI: 10.1007/s13337-017-0393-5.
|
| [8] |
POL S, PARLATI L, JADOUL M. Hepatitis C virus and the kidney[J]. Nat Rev Nephrol, 2019, 15(2):73-86. DOI: 10.1038/s41581-018-0081-8.
|
| [9] |
ILIESCU L, MERCAN-STANCIU A, TOMA L, et al. A severe case of hyperglycemia in a kidney transplant recipient undergoing interferon-free therapy for chronic hepatitis C[J]. Acta Endocrinol (Buchar), 2018, 14(4):533-538. DOI: 10.4183/aeb.2018.533.
|
| [10] |
MORI UBALDINI F, STRATTA RJ, NUNEZ M. Delayed spontaneous hepatitis C virus elimination in a renal transplant patient following graft rejection[J]. Transpl Infect Dis, 2019, 21(3):e13079. DOI: 10.1111/tid.13079.
|
| [11] |
DIZDAR OS, ERSOY A, AKSOY S, et al. Analysis of liver function test abnormalities in kidney transplant recipients: 7 year experience[J]. Pak J Med Sci, 2016, 32(6):1330-1335. DOI: 10.12669/pjms.326.10725.
|
| [12] |
LACKNER C, TINIAKOS D. Fibrosis and alcohol-related liver disease[J]. J Hepatol, 2019, 70(2):294-304. DOI: 10.1016/j.jhep.2018.12.003.
|
| [13] |
ALEGRE F, PELEGRIN P, FELDSTEIN AE. Inflammasomes in liver fibrosis[J]. Semin Liver Dis, 2017, 37(2):119-127. DOI: 10.1055/s-0037-1601350.
|
| [14] |
LAI M, AFDHAL NH. Liver fibrosis determination[J]. Gastroenterol Clin North Am, 2019, 48(2):281-289. DOI: 10.1016/j.gtc.2019.02.002.
|
| [15] |
ALTAMIRANO-BARRERA A, BARRANCO-FRAGOSO B, MÉNDEZ-SÁNCHEZ N. Management strategies for liver fibrosis[J]. Ann Hepatol, 2017, 16(1):48-56. DOI: 10.5604/16652681.1226814.
|
| [16] |
BANSAL MB, CHAMROONKUL N. Antifibrotics in liver disease: are we getting closer to clinical use?[J]. Hepatol Int, 2019, 13(1):25-39. DOI: 10.1007/s12072-018-9897-3.
|
| [17] |
LEI XF, FU W, KIM-KANEYAMA JR, et al. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice[J]. J Hepatol, 2016, 64(1):110-117. DOI: 10.1016/j.jhep.2015.08.026.
|
| [18] |
BARCENA-VARELA M, COLYN L, FERNANDEZ-BARRENA MG. Epigenetic mechanisms in hepatic stellate cell activation during liver fibrosis and carcinogenesis[J]. Int J Mol Sci, 2019, 20(10): E2507. DOI: 10.3390/ijms20102507.
|
| [19] |
ALRIC L, DI-MARTINO V, SELVES J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection[J]. Gastroenterology, 2002, 123(5):1494-1499. doi: 10.1053/gast.2002.36610
|
| [20] |
ROTH D, GAYNOR JJ, REDDY KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C[J]. J Am Soc Nephrol, 2011, 22(6):1152-1160. DOI: 10.1681/ASN.2010060668.
|
| [21] |
TUÑÓN MJ, SÁNCHEZ-CAMPOS S, GUTIÉRREZ B, et al. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes[J]. Biochem Pharmacol, 2003, 66(3):439-445. doi: 10.1016/S0006-2952(03)00288-0
|
| [22] |
MANOJLOVIC Z, BLACKMON J, STEFANOVIC B. Tacrolimus (FK506) prevents early stages of ethanol induced hepatic fibrosis by targeting LARP6 dependent mechanism of collagen synthesis[J]. PLoS One, 2013, 8(6):e65897. DOI: 10.1371/journal.pone.0065897.
|
| [23] |
FU J, BECKER C, CAO L, et al. Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency[J]. Bioorg Med Chem, 2018, 26(4):957-969. DOI: 10.1016/j.bmc.2017.09.008.
|
| [24] |
ALBEKAIRY AM, ABDEL-RAZAQ WS, ALKATHERI AM, et al. The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation[J]. Int J Health Sci (Qassim), 2018, 12(4):78-87.
|
| [25] |
ISHⅡ N, WATASHI K, HISHIKI T, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication[J]. J Virol, 2006, 80(9):4510-4520. doi: 10.1128/JVI.80.9.4510-4520.2006
|
| [26] |
NAKAGAWA M, SAKAMOTO N, TANABE Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins[J]. Gastroenterology, 2005, 129(3):1031-1041. doi: 10.1053/j.gastro.2005.06.031
|
| [27] |
FIRPI RJ, ZHU H, MORELLI G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation[J]. Liver Transpl, 2006, 12(1):51-57. doi: 10.1002/lt.20532
|
| [28] |
DONG S, GENG L, SHEN MD, et al. Natural killer cell activating receptor NKG2D is involved in the immunosuppressive effects of mycophenolate mofetil and hepatitis B virus infection[J]. Am J Med Sci, 2015, 349(5):432-437. DOI: 10.1097/MAJ.0000000000000442.
|
| [29] |
YE L, LI J, ZHANG T, et al. Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells[J]. Virus Res, 2012, 168(1/2):33-40. DOI: 10.1016/j.virusres.2012.06.009.
|
| [30] |
MORATH C, SCHWENGER V, BEIMLER J, et al. Antifibrotic actions of mycophenolic acid[J]. Clin Transplant, 2006, 20 (Suppl 17):25-29.
|
| [31] |
CHANG HW, WU VC, WU KD, et al. In rat renal fibroblasts, mycophenolic acid inhibits proliferation and production of the chemokine CCL2, stimulated by tumour necrosis factor-alpha[J]. Br J Pharmacol, 2010, 160(7):1611-1620. DOI: 10.1111/j.1476-5381.2010.00837.x.
|
| [32] |
GUO H, LEUNG JC, CHAN LY, et al. Modulation of intra-pulmonary TGF-beta expression by mycophenolate mofetil in lupus prone MRL/lpr mice[J]. Lupus, 2005, 14(8):583-592. doi: 10.1191/0961203305lu2170oa
|
| [33] |
NAKA K, IKEDA M, ABE K, et al. Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha[J]. Biochem Biophys Res Commun, 2005, 330(3):871-879. doi: 10.1016/j.bbrc.2005.03.062
|
| [34] |
PATSENKER E, SCHNEIDER V, LEDERMANN M, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis[J]. J Hepatol, 2011, 55(2):388-398. DOI: 10.1016/j.jhep.2010.10.044.
|
| [35] |
BIECKER E, DE GOTTARDI A, NEEF M, et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms[J]. J Pharmacol Exp Ther, 2005, 313(3):952-961. doi: 10.1124/jpet.104.079616
|
| [36] |
CZAJA AJ, CARPENTER HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis[J]. Hepatology, 2004, 39(6):1631-1638. doi: 10.1002/hep.20235
|
| [37] |
KNIGHT SR. Routine adherence monitoring after renal transplantation[J]. Transpl Int, 2019, 32(6):600-602. DOI: 10.1111/tri.13422.
|
| [38] |
KASISKE BL, ZEIER MG, CHAPMAN JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary[J]. Kidney Int, 2010, 77(4):299-311. DOI: 10.1038/ki.2009.377.
|
Figures(2)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad:
